Interestingly, MCL1 was demonstrated to also mediate resistance against targeted therapies including BRAF inhibitors31, receptor tyrosine kinase inhibitors32,33 and multikinase inhibitors34,35 that are commonly used in modern cancer therapy. Here, MCL1 is linked to cancer.